What is Pentadeca Arginate?
Pentadeca Arginate — commonly abbreviated PDA and also marketed as Pentadecapeptide Arginate or BPC-157 Arginate — is the arginate-salt form of BPC-157. It carries the same 15-amino-acid pentadecapeptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), the only difference being an arginine counter-ion in place of BPC-157’s acetate. PDA is not a new peptide sequence — it is a different salt of a well-studied molecule.
The main claim made for the arginate form is improved stability, particularly in acidic/gastric conditions. This is best understood as a vendor and marketing claim supported by thin data rather than an established, peer-reviewed fact. There is currently no published head-to-head evidence demonstrating that the arginate salt is clinically superior to acetate BPC-157.
Because the underlying molecule is identical, PDA’s studied mechanisms are inherited from the BPC-157 research base: angiogenesis (blood vessel formation), collagen synthesis, cytoprotection, and modulation of growth-factor and nitric oxide signaling. This work is predominantly preclinical (animal models); robust human clinical trials are lacking. PDA is not an approved medicine and is sold as a research chemical.
The 10mg vial provides extended research duration, ideal for protocols requiring consistent daily dosing over several weeks or months.
Quick Reference
| Parameter | Value |
|---|---|
| Peptide Amount | 10mg |
| Recommended BAC Water | 2mL |
| Resulting Concentration | 5mg/mL (5000mcg/mL) |
| Typical Research Dose | 250-500mcg (community-reported) |
| Frequency | 1-2x daily |
| Research Duration | 4-12 weeks |
Reconstitution Guide
Materials Needed
- Pentadeca Arginate 10mg lyophilized vial
- Bacteriostatic water (BAC water)
- Insulin syringes (U-100, 29-31 gauge)
- Alcohol swabs
- Sharps container
Step-by-Step Instructions
-
Prepare your workspace — Clean your work area and gather all materials. Wash hands thoroughly.
-
Clean the vial stoppers — Wipe the Pentadeca Arginate vial stopper and BAC water vial with alcohol swabs. Allow to dry.
-
Draw the BAC water — Using a sterile syringe, draw 2mL of bacteriostatic water.
-
Add water to peptide vial — Insert the needle and slowly inject BAC water down the inside wall of the vial. Never spray directly onto the powder.
-
Allow to dissolve — PDA dissolves quickly, usually within 1-2 minutes. Gently swirl if needed — never shake.
-
Verify dissolution — Solution should be clear and colorless. Discard if cloudy or particles visible.
-
Label and store — Write reconstitution date on vial. Refrigerate immediately.
Alternative Reconstitution Options
| BAC Water | Concentration | Best For |
|---|---|---|
| 2mL | 5mg/mL | Standard concentration |
| 4mL | 2.5mg/mL | Matches 5mg vial math |
| 5mL | 2mg/mL | Very precise low-dose measurements |
Dosage Protocol
Note on doses: The doses below reflect community-reported research use inherited from BPC-157 practice. They are not clinically established for Pentadeca Arginate, which has no dedicated human dosing studies.
Concentration Calculations
With 10mg peptide in 2mL BAC water:
- Concentration: 5mg/mL = 5000mcg/mL
- Per unit (U-100 syringe): 50mcg per unit
Common Dose Calculations
| Desired Dose | Draw Volume | Syringe Units |
|---|---|---|
| 100mcg | 0.02mL | 2 units |
| 250mcg | 0.05mL | 5 units |
| 300mcg | 0.06mL | 6 units |
| 500mcg | 0.10mL | 10 units |
| 750mcg | 0.15mL | 15 units |
| 1000mcg (1mg) | 0.20mL | 20 units |
Doses Per Vial
At 5mg/mL concentration (2mL total = 10mg):
| Daily Dose | Doses Per Vial | Duration |
|---|---|---|
| 250mcg | 40 doses | 40 days |
| 500mcg | 20 doses | 20 days |
| 500mcg 2x/day | 10 days | 10 days |
| 750mcg | ~13 doses | 13 days |
Suggested Research Protocols
Protocol A: Standard Healing Research
- Dose: 250-300mcg
- Frequency: 2x daily (AM and PM)
- Duration: 4-8 weeks
Protocol B: Systemic Support
- Dose: 500mcg
- Frequency: Once daily
- Duration: 4-12 weeks
Protocol C: Targeted/Localized
- Dose: 250mcg
- Frequency: Once daily near target area
- Duration: 2-4 weeks
Injection Guide
Subcutaneous Administration (Most Common)
- Clean injection site with alcohol swab
- Pinch skin fold at abdomen or near research area
- Insert needle at 45-90° angle
- Inject slowly
- Wait 5 seconds before withdrawing
- Apply gentle pressure — do not massage
Site Selection
For systemic effects:
- Abdomen (rotate sites)
- Subcutaneous fat areas
For localized research (optional):
- Inject subcutaneously near the area of interest
- Like BPC-157, PDA is expected to work systemically, but some protocols suggest local administration
Timing Considerations
- Can be administered with or without food
- If dosing 2x daily, space doses 8-12 hours apart
- Consistent timing recommended for research protocols
Storage Requirements
Lyophilized (Powder Form)
- Temperature: -20°C (-4°F) or colder
- Duration: 2+ years
- Conditions: Protect from light and moisture
Reconstituted (Mixed with BAC Water)
- Temperature: 2-8°C (36-46°F)
- Duration: 4-6 weeks
- Conditions: Protect from light, never freeze
Stability Notes
- The arginate salt is marketed as offering improved stability versus acetate BPC-157, but this claim is not backed by robust published data
- Solution should remain clear throughout use
- Discard if any cloudiness or particles develop
Research Considerations
Mechanism of Action
Because PDA shares BPC-157’s sequence, its research applications are understood through the same pathways:
- Angiogenesis: Promotes blood vessel formation (VEGF modulation)
- Collagen synthesis: Supports connective-tissue repair processes
- Growth factors: Influences EGF, FGF, and related growth factors
- Nitric oxide system: Modulates NO pathways for vascular effects
- Cytoprotection: Protective effects on various tissue types
Key Research Areas
Published research on the parent molecule (BPC-157) has examined contexts including:
- Tendon and ligament healing models
- Muscle injury recovery
- Gastrointestinal protection and healing
- Bone fracture healing
- Nerve damage repair
- Inflammatory conditions
Note that this evidence base is predominantly animal-model work; well-controlled human trials are lacking, and there are no PDA-specific clinical studies.
Pharmacokinetics
PDA has no dedicated pharmacokinetic study. Its behavior is expected to mirror BPC-157, which in rats shows a very short intravenous half-life (~15 minutes). This is an animal-by-analogy estimate, not human data.
Why Choose 10mg Vials
The 10mg vial offers advantages:
- Extended duration — 20-40 days depending on dose
- Cost efficiency — Lower per-mg cost than 5mg vials
- Protocol flexibility — Supports various dosing regimens
- Convenience — Fewer reconstitutions needed
Sourcing for Research
Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.
Scientific References
- Xu C, et al. “Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in rats and dogs.” Front Pharmacol. 2022;13:1026182.
- Sikiric P, et al. “Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract.” Curr Pharm Des. 2016;22(34):5207-5215.
Note: There is currently no Pentadeca Arginate-specific clinical reference. The citations above pertain to BPC-157, the identical peptide sequence from which PDA is derived.
Last updated: July 15, 2026
Disclaimer: This information is for educational and research purposes only. Pentadeca Arginate is a research peptide not intended for human consumption. Always follow applicable laws and institutional guidelines.